DGAP-News: STRATEC SE
/ Key word(s): AGM/EGM
STRATEC’S ANNUAL GENERAL MEETING APPROVES DIVIDEND INCREASE AND EXTENSION TO SUPERVISORY BOARD Birkenfeld, May 20, 2022 At today’s Annual General Meeting of STRATEC SE (Frankfurt: SBS; Prime Standard, SDAX), the company’s shareholders approved all agenda items submitted for resolution with clear majorities. As in the past two years, the Annual General Meeting was held on a virtual basis. As proposed, STRATEC will be distributing a dividend of € 0.95 per share to its shareholders for the past 2021 financial year (previous year: € 0.90). The distribution total amounts to € 11.5 million and will be paid out to shareholders via their depositing banks on May 25, 2022. This represents the eighteenth consecutive increase in the dividend since payment of the first dividend in 2004. Shareholders also approved the actions of the Board of Management and of the Supervisory Board and elected Ebner Stolz GmbH & Co. KG, Stuttgart, as auditor for the 2022 financial year. Furthermore, the remuneration report for the 2021 financial year was presented to and approved by the Annual General Meeting. Moreover, the Annual General Meeting also voted in favor of extending the Supervisory Board of STRATEC SE from three to four members to account for external requirements and the company’s targets in respect of diversity, and to further increase the range of experience available within the Supervisory Board. In electing Supervisory Board members, the Annual General Meeting approved the proposals submitted by the Supervisory Board. Prof. Dr. Georg Heni was newly elected to the Supervisory Board and will succeed the Supervisory Board Chairman, Dr. Rudolf Eugster, who as planned did not stand for reelection. Dr. med Patricia Geller was also newly elected to the Supervisory Board of STRATEC SE as its fourth member. At its constitutive meeting held directly after the Annual General Meeting, the Supervisory Board of STRATEC SE elected Prof. Dr. Georg Heni as its Chairman and reelected Dr. Frank Hiller as its Deputy Chairman. Overall, 80.7 percent of the company’s share capital was represented at the virtual Annual General Meeting. Further information about the Annual General Meeting can be found at www.stratec.com/agm, where details of voting results have also been published. ABOUT STRATEC The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies. Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange. FURTHER INFORMATION IS AVAILABLE FROM:
20.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | STRATEC SE |
Gewerbestr. 37 | |
75217 Birkenfeld | |
Germany | |
Phone: | +49 (0)7082 7916 0 |
Fax: | +49 (0)7082 7916 999 |
E-mail: | info@stratec.com |
Internet: | www.stratec.com |
ISIN: | DE000STRA555 |
WKN: | STRA55 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1358211 |
End of News | DGAP News Service |
|
1358211 20.05.2022
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.